



VIRGINIA COMMONWEALTH UNIVERSITY TO BECOME THIRD U.S. SITE FOR VISABL-AFL

21 January 2026 – Melbourne, Australia (**20 January 2026** – Minneapolis, MN United States) – **Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR)** is pleased to announce that the Institutional Review Board (**IRB**) of Virginia Commonwealth University Health (**VCU Health**) has approved VCU Health's enrolment in Imricor's VISABL-AFL clinical trial, supporting the U.S. FDA approval process for Imricor's ablation products. VCU Health is now the third U.S. site approved to join the trial.

Next steps include final budgeting, installation, and training, all expected to be completed in February. Procedures are expected to commence in March.

The Principal Investigator for VISABL-AFL at VCU Health is Dr. Ajay Pillai MD.

Dr. Pillai commented: “Imricor’s Northstar mapping system and Vision-MR mapping and ablation catheters represent a paradigm shift in cardiac ablation. The potential to visualize arrhythmogenic substrate and, crucially, the effects of ablation is extraordinarily impactful and meaningful for patient outcomes. The team at Virginia Commonwealth University is excited to be involved in the VISABL-AFL trial and look forward to a robust study.”

VCU is an academic health system associated with Virginia Commonwealth University in Richmond, Virginia, USA. VCU Health's VCU Medical Center includes an 800-plus-bed hospital and nationally ranked specialty programs. Newsweek and U.S. News & World Report consistently recognize it as one of the **leading hospitals in Virginia and nationwide**.

Imricor’s Chair and CEO, Steve Wedan, added: “We are very excited to have Dr. Pillai and the VCU team join VISABL-AFL, and we look forward to commencing procedures there in short order. This is yet another U.S. site that has moved with purpose and urgency to join the trial and support our FDA processes.”

ENDS

Authorised for release by Steve Wedan, Executive Chair, President, and CEO

Media and Investor Relations Contacts:

Simon Hinsley
Executive Director, NWR
simon@nwrccommunications.com.au
+61 401 909 653

Nick Corkill
VP Corporate Strategy, Imricor
nick.corkill@imricor.com
+61 450 475 633



About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is striving to make interventional medical procedures better, safer, and more cost effective by making it possible for these procedures to be performed under real-time magnetic resonance imaging (MRI) guidance, rather than under x-ray fluoroscopy guidance, thus taking advantage of MRI's superior imaging capabilities.

Imricor's Products

Imricor is a pioneer and world leader in developing MRI-compatible products for cardiac catheter ablation procedures. The Company's products include capital equipment, such as the NorthStar® Mapping System and the Advantage-MR® EP Recorder/Stimulator. Single-use devices include a variety of ablation catheters, diagnostic catheters, steerable sheaths, and other tools used for cardiac ablations.

Imricor's products are approved in the European Union, the Kingdom of Saudi Arabia, and New Zealand. US FDA approval is in process, and further approvals in other geographies such as Australia are being planned.

Foreign Ownership Restrictions

Imricor's CHESS Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

For personal use only